Table 1 Echocardiographic parameters
From: Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation
Parameter | Control (n = 6) | Control + Losartan (n = 3) | Succinate (n = 8) | Suc + Losartan (n = 5) |
|---|---|---|---|---|
Cardiac output (mL/min) | 52.17 ± 5.029 | 52.67 ± 4.7 | 68.03 ± 2.9* | 56.14 ± 3.12 |
LV ejection fraction (%) | 71.74 ± 3.02 | 75.43 ± 1.78 | 74.00 ± 1 | 71.76 ± 1.00 |
LV fraction shortening (%) | 40.95 ± 2.57 | 45.20 ± 1.81 | 43.42 ± 0.9 | 41.87 ± 0.87 |
LVd (μL) | 180.00 ± 9.7 | 203.90 ± 8.5 | 245.20 ± 10.11# | 209.30 ± 12.09 |
LV systolic volume (μL) | 72.98 ± 6.34 | 44.64 ± 7.31 | 62.70 ± 7.53 | 57.06 ± 3.9 |
Stroke volume (μl) | 136.70 ± 12.63 | 137.20 ± 12.99 | 167.50 ± 7.34# | 142.10 ± 6.9 |
Heart rate (bpm) | 398.00 ± 9.2 | 399.40 ± 10.19 | 402.90 ± 7.9 | 393.60 ± 17.18 |
LVIDd (mm) | 6.15 ± 0.22 | 6.32 ± 0.11 | 6.99 ± 0.09# | 6.50 ± 0.15& |
LVIDs (mm) | 3.02 ± 0.06 | 3.49 ± 0.14 | 3.96 ± 0.10# | 3.70 ± 0.10* |